Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure

BACKGROUND: Re‐biopsy is important for exploring resistance mechanisms, especially for non‐small cell lung cancer (NSCLC) patients who develop resistance to EGFR‐tyrosine kinase inhibitors (TKIs). Liquid biopsy using circulating tumor DNA has come into use for this purpose. This retrospective study...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Zhou, Juan, Zhao, Chao, Zhao, Jing, Wang, Qi, Chu, Xiangling, Li, Jiayu, Zhou, Fei, Ren, Shengxiang, Li, Xuefei, Su, Chunxia, Zhou, Caicun
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6449239/
https://ncbi.nlm.nih.gov/pubmed/30887673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13035
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados